Our Research Trials
Our Clinical Trials and Studies
Research is fundamental to advancing medicine and improving care for people affected by memory problems. At MARC, every study we deliver brings us closer to better treatments and a future cure for dementia.
Our Open Trials
Open to new volunteers
PrevenTRON
PrevenTRON is a clinical study that will be testing if a study medication called Trontinemab can slow down or stop the development of symptoms related to Alzheimer’s disease in people who do not have problems with their memory or thinking. Trontinemab works by reducing the build-up of a protein called amyloid in the brain.
Our On-Going Trials
Closed to new volunteers
CLARITY-AD
CLARITY-AD is a placebo-controlled trial in the Open Label Extension Phase, investigating whether the drug, Lecanemab, helps slow the progression of Alzheimer’s disease.
%20(1).jpg)
COBALT
COBALT is a placebo-controlled trial investigating whether Memantine improves health and functioning for people with dementia with Lewy bodies. Memantine is already licensed to help treat symptoms in Alzheimer's disease.
COGNIKET-MCI
COGNIKET-MCI is a placebo-controlled trial investigating whether ketones and B vitamins help cognitive function for people with Mild Cognitive Impairment.
MK2214-004
MK2214-004 is a placebo-controlled trial testing MK-2214 to treat Alzheimer’s disease in people Mild Cognitive Impairment or mild dementia due to early Alzheimer’s disease.
PEBBAL2
PEBBAL2 is an observational study investigating how the permeability of the blood brain barrier and inflammation might contribute to cognitive decline in Alzheimer's disease.
POLARIS-AD
POLARIS-AD is a placebo-controlled trial investigating whether the drug, AR1001, may help the blood vessels in the brain work better for people with Alzheimer's disease.
TrailRunner
TrailRunner is a placebo-controlled trial evaluating whether the drug Remternetug is safe and effective at slowing the onset of Alzheimer’s disease in people who are at risk.
.jpg)
TRAILBLAZER5
TRAILBLAZER5 is a placebo-controlled trial investigating whether the drug, Donanemab, may help slow the progression of Alzheimer’s disease.